tiprankstipranks
Trending News
More News >
Ipsen (FR:IPN)
:IPN

Ipsen (IPN) AI Stock Analysis

Compare
16 Followers

Top Page

FR

Ipsen

(LSE:IPN)

Rating:69Neutral
Price Target:
€112.00
▲(9.27%Upside)
Ipsen's strong financial performance and robust balance sheet are the primary strengths. However, mixed technical indicators and a relatively high valuation constrain the overall score. Continuous focus on profitability and cash flow management will be key to future improvements.

Ipsen (IPN) vs. iShares MSCI France ETF (EWQ)

Ipsen Business Overview & Revenue Model

Company DescriptionIpsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
How the Company Makes MoneyIpsen makes money primarily through the development, production, and sale of pharmaceutical products across its key therapeutic areas: oncology, neuroscience, and rare diseases. Revenue is generated from product sales, licensing agreements, and partnerships. The company's oncology segment, which includes treatments for various cancers, is a significant contributor to its earnings. Ipsen also engages in strategic partnerships and collaborations with other pharmaceutical companies to enhance its research capabilities and expand its product offerings. Additionally, the company invests in research and development to innovate and bring new drugs to market, which supports long-term revenue growth.

Ipsen Financial Statement Overview

Summary
Ipsen presents a stable financial position with strong revenue growth and efficient operations. The company's balance sheet is solid, with decreasing leverage and strong equity. However, the declining net profit margin and free cash flow growth rate present areas for improvement.
Income Statement
75
Positive
Ipsen has shown a strong revenue growth rate over the years, with a notable increase from 2023 to 2024. The gross profit margin is healthy, indicating efficient cost management relative to revenue. However, the net profit margin has decreased, suggesting increased expenses or lower profitability. The EBIT and EBITDA margins remain steady, reflecting consistent operational efficiency.
Balance Sheet
80
Positive
Ipsen's balance sheet is robust with a strong equity base and a decreasing debt-to-equity ratio over the years, highlighting financial stability. The return on equity shows effective utilization of shareholder funds, although it has declined recently. The equity ratio is solid, indicating a strong ownership stake in the company.
Cash Flow
70
Positive
The cash flow statement shows a mixed picture with a significant drop in free cash flow in 2024 compared to 2023. However, operating cash flow remains strong, with a high operating cash flow to net income ratio, indicating good cash generation relative to profit. The decline in free cash flow growth rate is a concern that needs addressing.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.57B3.31B3.16B2.75B2.69B
Gross Profit2.96B2.74B2.63B2.31B2.20B
EBITDA1.16B1.14B1.13B1.06B794.40M
Net Income345.90M644.40M648.60M646.60M548.00M
Balance Sheet
Total Assets6.44B6.32B5.61B4.99B4.31B
Cash, Cash Equivalents and Short-Term Investments679.20M528.40M1.17B814.70M642.50M
Total Debt426.80M306.10M771.60M786.60M1.17B
Total Liabilities2.26B2.50B2.27B2.25B2.18B
Stockholders Equity4.18B3.83B3.34B2.74B2.13B
Cash Flow
Free Cash Flow133.00M749.70M700.30M453.90M630.60M
Operating Cash Flow915.50M865.90M953.20M871.80M771.30M
Investing Cash Flow-676.60M-1.07B-458.60M-332.00M-163.70M
Financing Cash Flow-100.00M-458.40M-146.00M-400.30M-307.50M

Ipsen Technical Analysis

Technical Analysis Sentiment
Positive
Last Price102.50
Price Trends
50DMA
100.95
Positive
100DMA
104.43
Negative
200DMA
107.93
Negative
Market Momentum
MACD
0.11
Positive
RSI
50.85
Neutral
STOCH
60.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IPN, the sentiment is Positive. The current price of 102.5 is below the 20-day moving average (MA) of 103.03, above the 50-day MA of 100.95, and below the 200-day MA of 107.93, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 50.85 is Neutral, neither overbought nor oversold. The STOCH value of 60.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:IPN.

Ipsen Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
FRIPN
69
Neutral
€8.48B24.538.89%1.18%8.73%-46.34%
59
Neutral
£5.89B9.26-57.69%4.75%14.48%-6.99%
€14.07B32.6110.86%0.75%
€11.09B28.449.66%0.85%
€866.86M14.7110.64%1.06%
€2.63B18.1514.95%0.46%
$117.89B19.997.34%4.56%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:IPN
Ipsen
102.50
-10.77
-9.51%
GB:0RUG
bioMerieux
119.54
30.11
33.67%
GB:0MV5
Eurofins Scientific
60.63
14.41
31.18%
GB:0O1O
VETOQUINOL
73.20
-19.88
-21.36%
GB:0NM7
Virbac SA
315.00
-21.48
-6.38%
SNYNF
Sanofi
96.05
1.55
1.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025